U.S. Markets closed
  • S&P 500

    4,167.59
    +2.93 (+0.07%)
     
  • Dow 30

    34,230.34
    +97.31 (+0.29%)
     
  • Nasdaq

    13,582.42
    -51.08 (-0.37%)
     
  • Russell 2000

    2,241.37
    -6.92 (-0.31%)
     
  • Crude Oil

    65.31
    -0.32 (-0.49%)
     
  • Gold

    1,786.60
    +2.30 (+0.13%)
     
  • Silver

    26.57
    +0.04 (+0.16%)
     
  • EUR/USD

    1.2011
    -0.0004 (-0.0360%)
     
  • 10-Yr Bond

    1.5840
    -0.0080 (-0.50%)
     
  • Vix

    19.15
    -0.33 (-1.69%)
     
  • GBP/USD

    1.3907
    +0.0019 (+0.1335%)
     
  • USD/JPY

    109.2130
    -0.0920 (-0.0842%)
     
  • BTC-USD

    57,144.63
    +3,106.49 (+5.75%)
     
  • CMC Crypto 200

    1,457.26
    +51.96 (+3.70%)
     
  • FTSE 100

    7,039.30
    +116.13 (+1.68%)
     
  • Nikkei 225

    28,812.63
    -241.37 (-0.83%)
     

Acer Therapeutics to Participate in March Virtual Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
Acer Therapeutics Inc.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEWTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Life Sciences Virtual Conference and the 33rd Annual Roth Virtual Conference.

Conference:

H.C. Wainwright Global Life Sciences Virtual Conference

Dates:

March 9-10, 2021

Format:

One-on-one virtual meetings

Conference:

33rd Annual Roth Virtual Conference

Format:

Panel Presentation and one-on-one virtual meetings

Panel:

Therapeutics Against SARS-CoV-2

Date:

Monday, March 15, 2021

Time:

12 p.m. Eastern Time

Webcast:

https://acertx.com/investor-relations/events-presentations/

About Acer Therapeutics Inc.
Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms (iVMS); and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. For more information, visit www.acertx.com.

Investor Contact:
Hans Vitzthum
LifeSci Advisors
Ph: 617-430-7578
hans@lifesciadvisors.com

Jim DeNike
Acer Therapeutics Inc.
Ph: 844-902-6100
jdenike@acertx.com